189 related articles for article (PubMed ID: 22022296)
1. Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors.
Kim HS; Lee HS; Kim WH
Cancer Res Treat; 2011 Sep; 43(3):181-8. PubMed ID: 22022296
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors.
Watanabe H; Fujishima F; Komoto I; Imamura M; Hijioka S; Hara K; Yatabe Y; Kudo A; Masui T; Tsuchikawa T; Sakamoto K; Shiga H; Nakamura T; Nakaya N; Motoi F; Unno M; Sasano H
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159042
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.
Kim JY; Kim J; Kim YI; Yang DH; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
Sci Rep; 2024 Feb; 14(1):4047. PubMed ID: 38374188
[TBL] [Abstract][Full Text] [Related]
4. The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience.
Mohamed A; Asa SL; Lee Z; Tirumani SH; Li Q; Avril N; Bajor D; Mahipal A; Chakrabarti S; Selfridge JE; Kardan A
J Gastrointest Oncol; 2023 Apr; 14(2):1087-1094. PubMed ID: 37201086
[TBL] [Abstract][Full Text] [Related]
5. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.
Wang Y; Wang W; Jin K; Fang C; Lin Y; Xue L; Feng S; Zhou Z; Shao C; Chen M; Yu X; Chen J
Oncol Lett; 2017 Mar; 13(3):1165-1174. PubMed ID: 28454229
[TBL] [Abstract][Full Text] [Related]
8. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
9. Circulating hsa-miR-5096 predicts
Bocchini M; Tazzari M; Ravaioli S; Piccinini F; Foca F; Tebaldi M; Nicolini F; Grassi I; Severi S; Calogero RA; Arigoni M; Schrader J; Mazza M; Paganelli G
Front Oncol; 2023; 13():1136331. PubMed ID: 37287922
[TBL] [Abstract][Full Text] [Related]
10. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes.
Pinato DJ; Tan TM; Toussi ST; Ramachandran R; Martin N; Meeran K; Ngo N; Dina R; Sharma R
Br J Cancer; 2014 Jan; 110(1):115-22. PubMed ID: 24231952
[TBL] [Abstract][Full Text] [Related]
11. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.
Qian ZR; Li T; Ter-Minassian M; Yang J; Chan JA; Brais LK; Masugi Y; Thiaglingam A; Brooks N; Nishihara R; Bonnemarie M; Masuda A; Inamura K; Kim SA; Mima K; Sukawa Y; Dou R; Lin X; Christiani DC; Schmidlin F; Fuchs CS; Mahmood U; Ogino S; Kulke MH
Pancreas; 2016 Nov; 45(10):1386-1393. PubMed ID: 27622342
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
13. RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer.
Han G; Hwang E; Lin F; Clift R; Kim D; Guest M; Bischoff E; Moran S; Li G
Mol Cancer Ther; 2023 Dec; 22(12):1434-1443. PubMed ID: 37616528
[TBL] [Abstract][Full Text] [Related]
14. Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer.
Qiu CZ; Wang C; Huang ZX; Zhu SZ; Wu YY; Qiu JL
World J Gastroenterol; 2006 Apr; 12(13):2011-5. PubMed ID: 16610049
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy.
Zhao WY; Zhuang C; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Ling TL; Cao H; Zhang ZG
Am J Transl Res; 2014; 6(6):831-40. PubMed ID: 25628793
[TBL] [Abstract][Full Text] [Related]
16. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
17. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study.
; Cho MY; Kim JM; Sohn JH; Kim MJ; Kim KM; Kim WH; Kim H; Kook MC; Park DY; Lee JH; Chang H; Jung ES; Kim HK; Jin SY; Choi JH; Gu MJ; Kim S; Kang MS; Cho CH; Park MI; Kang YK; Kim YW; Yoon SO; Bae HI; Joo M; Moon WS; Kang DY; Chang SJ
Cancer Res Treat; 2012 Sep; 44(3):157-65. PubMed ID: 23091441
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
[TBL] [Abstract][Full Text] [Related]
19. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
20. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
